JPRN-UMIN000005137CompletedPhase 3
Examination of clinical utility of XX-45(double-balloon enteroscope) - Examination of clinical utility of double-balloon enteroscope
Conditions
Trial Snapshot
- Phase
- Phase 3
- Status
- Completed
- Sponsor
- FUJIFILM Corporation
- Enrollment
- 120
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 13years-old to 79years-old (—)
- Sex
- All
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1)Patients with acute abdomen 2)Patients with severe acute inflammation 3)Patients with anaphylaxis to natural rubber 4)Patients in a very bad general condition 5)Patients with suspected intestinal perforation 6)Patients having severe blood clotting defect 7)Patients with severe hepatic function disorder 8)Patients with severe respiratory diseases or circulatory diseases 9)Gravida and possibly pregnant patients 10)Patients who have participated in other clinical trials within 3 months prior to the start of this trial. 11)Patients who do not have the capacity or intention to cooperate with the trial procedures. 12)Patients who have experienced any adverse reactions through the enteroscopy. 13)Patients, the investigator (or the subinvestigator) considers, inappropriate for entry into the trial. 14)Sick or injured persons in life-threatening conditions and from whom it seems difficult to obtain written informed consent for their participation in the trial. 15)Patients with whom insertion of the endoscope has to be conducted via the stoma.
Investigators
Similar Trials
Completed
Phase 2
A clinical study of Liv.52 GNX tablet in Alcoholic liver diseaseCTRI/2018/03/012751The Himalaya Drug Company40
Active, not recruiting
Phase 2
Clinical trial of Liv.52 GNX tablets in liver damage due to tuberculosis drugs.CTRI/2018/01/011565The Himalaya Drug Company
Active, not recruiting
Not Applicable
Safety and Efficacy of XM 02 in patients with Non-Hodgkin-Lymphoma receiving chemotherapy.EUCTR2004-001449-13-LTBioGeneriX AG90
Active, not recruiting
Not Applicable
Safety and Efficacy of XM 02 in patients with Non-Hodgkin-Lymphoma receiving chemotherapy.Patients with Non-Hodgkin-Lymphoma receiving chemotherapy and developing Neutropenia due to chemotherapy.EUCTR2004-001449-13-HUBioGeneriX AG90
Active, not recruiting
Phase 1
A phase II Clinical Study of CP-4055 as second line therapy in patients with advanced colorectal cancer - CP4055-202A phase II clinical study of ELACYT as second line therapy in patients with advanced colorectal cancerEUCTR2006-006766-41-GBClavis Pharma ASA42
